Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Safety and Tolerability of Isradipine (A Potential Neuroprotective Agent) in Patients With Parkinson's Disease- Stage II

NCT00753636 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT00753636
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00753636 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Safety and Tolerability of Isradipine (A Potential Neuroprotective Agent) in Patients With Parkinson's Disease- Stage II
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2008
Completion date
February 28, 2010
Enrollment
31 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease